Helus Pharma's Depression Drug Update Due Nov. 9

Healthcare operators tracking mental health treatment pipelines can watch a scheduled webcast on late-stage depression and anxiety candidates.

Updated on Nov. 3, 2026 in Healthcare

Vector editorial illustration of plain amber vials in a row beside a large geometric lattice shaped like a receptor binding site, in teal, cream, and coral. — Helus Pharma CEO Michael Halstead will speak at the Guggenheim Healthcare Innovation Conference in Boston, webcast live November 9, 2026 at 3:00 p.m. EDT. AI Illustration. Upload story photo >

Helus Pharma CEO Michael Halstead will take part in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston, webcast live on November 9, 2026 at 3:00 p.m. EDT. The event is a scheduled investor-facing appearance, relevant to operators tracking clinical-stage mental health drug developers.

Why it matters

Investor-facing appearances at healthcare conferences are how clinical-stage companies communicate pipeline progress and capital needs to the market. For operators in healthcare services, vendors, and adjacent firms, updates from late-stage developers signal where mental health treatment investment is concentrating.

The webcast is scheduled for 3:00 p.m. EDT on November 9, 2026, with HLP003 in Phase 3 and HLP004 in Phase 2 development. The source provides no comparator financial or enrollment figures for the pipeline.

The players

Helus Pharma Inc.

A clinical-stage pharmaceutical company listed on Nasdaq and Cboe Canada as HELP, developing novel serotonergic agonists for mental health across Canada, the United States, the United Kingdom, and Ireland.

Michael Halstead

Chief Executive Officer of Helus Pharma, leading the company's clinical development of its serotonergic agonist pipeline.

U.S. Food and Drug Administration

The federal agency that regulates drug approval and granted Breakthrough Therapy Designation to Helus Pharma's HLP003 candidate.

The details

Helus Pharma is developing novel serotonergic agonists, a class of drugs designed to act on serotonin receptors for mental health conditions. Its lead candidate, HLP003, is in Phase 3 trials for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a program intended to speed development of drugs addressing serious conditions. A second candidate, HLP004, is in Phase 2 for generalized anxiety disorder.

November 9, 2026 at 3:00 p.m. EDT: CEO fireside chat webcast at the Guggenheim Healthcare Innovation Conference.
March 31, 2026: End of the fiscal year covered by the company's annual information form.

Market Landscape

Clinical-stage developers of serotonergic agonists are moving forward in a field where FDA Breakthrough Therapy Designation signals expedited review potential for HLP003. The November conference appearance is a standard venue for late-stage biotechs to update investors on trial progress and regulatory strategy.

Operators in healthcare services and vendors should note the scheduled November 9 webcast as a source of pipeline updates on mental health treatments. Firms planning around mental health drug launches should monitor the HLP003 Phase 3 progress that management is expected to address.

The takeaway

Businesses tracking mental health treatment investment should calendar the November 9, 2026 webcast and review the Events & Presentations page for the replay. Monitoring whether the company updates HLP003's Phase 3 timeline will indicate when the candidate could affect treatment-related service demand.